PEGylation, successful approach to drug delivery (Q28278538)

Protein kinases and phosphatases: the yin and yang of protein phosphorylation and signaling

Europe PubMed Central

title

PEGylation, successful approach to drug delivery (English)

0 references

1 reference

Gianfranco Pasut

2

0 references

author name string

Francesco M Veronese

series ordinal

1

0 references

language of work or name

English

0 references

publication date

1 November 2005

0 references

published in

Drug Discovery Today

0 references

volume

10

0 references

page(s)

1451-8

0 references

issue

21

0 references

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903575-0

7 January 2021

The biology and enzymology of protein N-myristoylation

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903575-0

7 January 2021

Posttranslational modifications of histones by methylation

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903575-0

7 January 2021

Strategies for drug discovery by targeting sulfation pathways

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903575-0

7 January 2021

Protein, peptide and non-peptide drug PEGylation for therapeutic application

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903575-0

7 January 2021

Pegaspargase: a review of clinical studies

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903575-0

7 January 2021

Adenosine deaminase deficiency with late onset of recurrent infections: response to treatment with polyethylene glycol-modified adenosine deaminase

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903575-0

7 January 2021

Rational design of a potent, long-lasting form of interferon: a 40 kDa branched polyethylene glycol-conjugated interferon alpha-2a for the treatment of hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903575-0

7 January 2021

Structural and biological characterization of pegylated recombinant interferon alpha-2b and its therapeutic implications

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903575-0

7 January 2021

Characterization and stability of N-terminally PEGylated rhG-CSF.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903575-0

7 January 2021

Therapeutic antibody fragments with prolonged in vivo half-lives

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903575-0

7 January 2021

Enzymatic procedure for site-specific pegylation of proteins

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903575-0

7 January 2021

Effects of PEG conjugation on insulin properties

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903575-0

7 January 2021

Selective alkylation and acylation of alpha and epsilon amino groups with PEG in a somatostatin analogue: tailored chemistry for optimized bioconjugates

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903575-0

7 January 2021

Hepatic excretion and metabolism of polyethylene glycols and mannitol in the cat

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903575-0

7 January 2021

Microbial degradation of polyethers

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903575-0

7 January 2021

Anchimeric assistance effect on regioselective hydrolysis of branched PEGs: a mechanistic investigation

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903575-0

7 January 2021

Functionalization of tumor necrosis factor-alpha using phage display technique and PEGylation improves its antitumor therapeutic window

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903575-0

7 January 2021

Optimal site-specific PEGylation of mutant TNF-alpha improves its antitumor potency

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903575-0

7 January 2021

Controlled release of proteins from their poly(ethylene glycol) conjugates: drug delivery systems employing 1,6-elimination

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903575-0

7 January 2021

PEGylated Proteins as Cancer Therapeutics

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903575-0

7 January 2021

Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903575-0

7 January 2021

Drug-polymer conjugates containing acid-cleavable bonds

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903575-0

7 January 2021

Drug delivery systems based on trimethyl lock lactonization: poly(ethylene glycol) prodrugs of amino-containing compounds

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903575-0

7 January 2021

Anticancer drug delivery systems: multi-loaded N4-acyl poly(ethylene glycol) prodrugs of ara-C. II. Efficacy in ascites and solid tumors

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903575-0

7 January 2021

CT-2103: a novel macromolecular taxane with potential advantages compared with conventional taxanes.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903575-0

7 January 2021

Nonionic polyethylene glycol-ferrioxamine as a renal magnetic resonance contrast agent

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903575-0

7 January 2021

Poly(ethylene glycol)-conjugated anti-EGF receptor antibody C225 with radiometal chelator attached to the termini of polymer chains

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903575-0

7 January 2021

Highly efficient technetium-99m labeling procedure based on the conjugation of N-[N-(3-diphenylphosphinopropionyl)glycyl]cysteine ligand with poly(ethylene glycol).

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903575-0

7 January 2021

Preclinical and phase 1A clinical evaluation of an anti-VEGF pegylated aptamer (EYE001) for the treatment of exudative age-related macular degeneration

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903575-0

7 January 2021

Beyond the red cell: pegylation of other blood cells and tissues

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903575-0

7 January 2021

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903575-0

1 reference

7 January 2021

10.1016/S1359-6446(05)03575-0

Identifiers

DOI

1 reference

Consolidated OpenCitations Corpus – April 2017

1033572

1033572

1 reference

Consolidated OpenCitations Corpus – April 2017

Consolidated OpenCitations Corpus – April 2017

1 reference